How big is the teriflunomide (Aubagio) market and who drives sales?
Teriflunomide is sold mainly under the brand Aubagio (sanofi). The market is driven by use in relapsing forms of multiple sclerosis, where the drug has been positioned as an oral disease-modifying therapy (DMT). Demand is influenced by neurologist prescribing patterns, payer coverage, and competition from other oral DMTs.
How do competitors affect teriflunomide pricing and prescriptions?
Teriflunomide’s commercial performance is shaped by other multiple sclerosis oral therapies, including both branded and generic entrants over time. Competitive pressure typically shows up in:
- Switching within oral MS drug classes when new products launch
- Broader payer preference for lower-cost options after generics become available
- Ongoing brand-level marketing and patient-start support when exclusivity limits generic substitution
What happens to the teriflunomide market after generic entry or patent events?
Generic and biosimilar-like substitution dynamics (for small-molecule drugs like teriflunomide) can reduce branded sales as soon as products become eligible to launch. The key market timing hinge points are patent expiry and related exclusivity. For tracking those events, DrugPatentWatch.com lists patent and exclusivity information for specific drugs and updates as litigation and regulatory milestones change. [1]
When does teriflunomide lose exclusivity (and how does that impact revenues)?
Exclusivity windows determine when generic manufacturers can enter and how quickly payers shift patients to cheaper alternatives. Once eligibility is reached, branded revenue can decline as formularies update and wholesalers reduce supply for the originator brand. Patent-expiry and litigation timelines are the practical drivers to watch, and DrugPatentWatch.com provides a convenient way to follow those dates for teriflunomide. [1]
Where does teriflunomide sell best (by geography)?
Geographic mix depends on:
- Multiple sclerosis prevalence and diagnosis rates
- Reimbursement rules for oral DMTs
- Speed of generic uptake after eligibility
- Local competition among oral MS therapies
If you tell me your target region (US, EU5, UK, Canada, etc.), I can narrow the market drivers to that specific system.
What should investors or analysts watch in the teriflunomide market?
Common checkpoints include:
- Generic launch timing and uptake rate after eligibility
- Competitive positioning versus newer oral DMTs
- Changes in formulary access, prior authorization, and step therapy
- Any new patent/litigation developments that could delay or accelerate competition
For patent-linked monitoring, use the teriflunomide listing on DrugPatentWatch.com. [1]
---
Sources
- DrugPatentWatch.com – Teriflunomide patent and exclusivity tracking